XOMA ROYALTY CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 25.4 USD | -0.78% |
|
-3.57% | -0.04% |
| Jul. 09 | Xoma Changes Name to Xoma Royalty | MT |
| Jul. 01 | XOMA Corporation(NasdaqGM:XOMA) added to Russell 3000 Growth Index | CI |
Financials (USD)
| Sales 2024 * | 21M | Sales 2025 * | 26.93M | Capitalization | 305M |
|---|---|---|---|---|---|
| Net income 2024 * | -22M | Net income 2025 * | -15M | EV / Sales 2024 * | 14.5 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 11.3 x |
| P/E ratio 2024 * |
-13.8
x | P/E ratio 2025 * |
-19.9
x | Employees | 13 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.47% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -0.78% | ||
| 1 week | -3.57% | ||
| Current month | -0.47% | ||
| 1 month | -0.47% | ||
| 3 months | +1.79% | ||
| 6 months | +2.21% | ||
| Current year | -0.04% |
1 week
25.31
25.86
1 month
25.1326.48
Current year
24.6126.48
1 year
21.4026.48
3 years
21.4027.50
5 years
21.4027.57
10 years
21.4027.57
| Managers | Title | Age | Since |
|---|---|---|---|
Owen Hughes
CEO | Chief Executive Officer | 49 | 22-12-31 |
Thomas Burns
DFI | Director of Finance/CFO | 50 | 06-08-13 |
Bradley Sitko
CIO | Chief Investment Officer | 43 | 23-01-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Heather Franklin
BRD | Director/Board Member | 58 | 21-08-05 |
| Chairman | 68 | 10-08-25 | |
Joseph Limber
BRD | Director/Board Member | 71 | 12-12-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.68% | 909 M€ | +3.62% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-11 | 25.4 | -0.78% | 691 |
| 24-07-10 | 25.6 | +0.30% | 939 |
| 24-07-09 | 25.52 | -0.92% | 1,753 |
| 24-07-08 | 25.76 | -0.50% | 2,743 |
| 24-07-05 | 25.89 | -1.71% | 1,294 |
Delayed Quote Nasdaq, July 11, 2024 at 04:30 pm EDT
More quotes
XOMA Royalty Corporation, formerly XOMA Corporation, is a biotechnology royalty aggregator. The Companyâs royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. Its royalty portfolio includes DAY101 (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, TAK-079 (mezagitamab), BAY-1213790 (osocimab), AFM13 (acimtamig), AB023 (gruticibart), AB002 (E-WE thrombin), AB054, AV-299 (ficlatuzumab), COM902, vosaroxin, aldoxorubicin, INCAGN2385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, G03-52-01, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], VABYSMO (faricimab-svoa), CMP-001 (vidutolimod), and CFZ533 (iscalimab).
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
26.18
USD
Average target price
58
USD
Spread / Average Target
+121.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +20.95% | 127B | |
| +23.00% | 117B | |
| +26.70% | 27.77B | |
| -19.75% | 20.44B | |
| -14.87% | 16.62B | |
| -16.56% | 15.92B | |
| +11.19% | 14.74B | |
| -46.65% | 14.94B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- XOMA Stock
- XOMAP Stock
